6dg2: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Antigen Binding Fragment of the Pan-ebolavirus Monoclonal Antibody 6D6== | |||
<StructureSection load='6dg2' size='340' side='right' caption='[[6dg2]], [[Resolution|resolution]] 1.96Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6dg2]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DG2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6DG2 FirstGlance]. <br> | |||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6dg2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dg2 OCA], [http://pdbe.org/6dg2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dg2 RCSB], [http://www.ebi.ac.uk/pdbsum/6dg2 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dg2 ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Ebola virus infection causes severe disease in humans and represents a global health threat. Candidates for immunotherapeutics and vaccines have shown promise in clinical trials, though they are ineffective against other members of the Ebolavirus genus which also cause periodic, lethal outbreaks. Here, we present a crystal structure of a pan-ebolavirus antibody, 6D6, as well as single particle electron microscopy reconstructions of 6D6 in complex with Ebola and Bundibugyo virus glycoproteins. 6D6 binds to the conserved glycoprotein fusion peptide, implicating it as a site of immune vulnerability that could be exploited to reliably elicit a pan-ebolavirus neutralizing antibody response. | |||
Structural Characterization of Pan-ebolavirus Antibody 6D6 Targeting the Fusion Peptide of the Surface Glycoprotein.,Milligan JC, Parekh DV, Fuller KM, Igarashi M, Takada A, Saphire EO J Infect Dis. 2018 Sep 10. pii: 5093891. doi: 10.1093/infdis/jiy532. PMID:30203042<ref>PMID:30203042</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 6dg2" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Milligan, J C]] | |||
[[Category: Saphire, E O]] | |||
[[Category: Antibody]] | |||
[[Category: Antigen binding fragment]] | |||
[[Category: Ebola]] | |||
[[Category: Fab]] | |||
[[Category: Immune system]] | |||
[[Category: Monoclonal]] | |||
Revision as of 11:03, 26 September 2018
Antigen Binding Fragment of the Pan-ebolavirus Monoclonal Antibody 6D6Antigen Binding Fragment of the Pan-ebolavirus Monoclonal Antibody 6D6
Structural highlights
Publication Abstract from PubMedEbola virus infection causes severe disease in humans and represents a global health threat. Candidates for immunotherapeutics and vaccines have shown promise in clinical trials, though they are ineffective against other members of the Ebolavirus genus which also cause periodic, lethal outbreaks. Here, we present a crystal structure of a pan-ebolavirus antibody, 6D6, as well as single particle electron microscopy reconstructions of 6D6 in complex with Ebola and Bundibugyo virus glycoproteins. 6D6 binds to the conserved glycoprotein fusion peptide, implicating it as a site of immune vulnerability that could be exploited to reliably elicit a pan-ebolavirus neutralizing antibody response. Structural Characterization of Pan-ebolavirus Antibody 6D6 Targeting the Fusion Peptide of the Surface Glycoprotein.,Milligan JC, Parekh DV, Fuller KM, Igarashi M, Takada A, Saphire EO J Infect Dis. 2018 Sep 10. pii: 5093891. doi: 10.1093/infdis/jiy532. PMID:30203042[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||